About keto diets and cancer

Debates arise frequently in the lung cancer community about reducing sugar intake to prevent and/or treat cancer. Some people claim a ketogenic diet is an effective cancer treatment, but rarely provide objective, scientific evidence to support this claim.

A recent article explored claims about the value of ketogenic diets for cancer patients. It was published in an open access journal and written by researchers at the University of Manchester in the UK. The article found high-quality evidence regarding ketogenic diets for cancer patients is lacking:

“High‐quality evidence on the effect of ketogenic diets on anthropometry, metabolism, QoL [quality of life] and tumour effects is currently lacking in oncology patients. Heterogeneity between studies and low adherence to diet affects the current evidence. There is an obvious gap in the evidence, highlighting the need for controlled trials to fully evaluate the intervention.”

You can read the full article here:

A systematic review of the use of ketogenic diets in adult patients with cancer

Take Action Today! Support restoring $20 million in lung cancer research funding

If you do nothing else today, DO THIS & PASS IT ON. Please ask your US Congressional Representative to support restoring $20M in funding for the Lung Cancer Research Program in 2020 before the March 26 sign-on deadline. It only takes a minute

https://www.votervoice.net/mobile/LCA/Campaigns/64484/Respond

Want to be a #lungcancer patient research advocate? Inaugural @IASLC STARS program application period is open!

    • Have you or a family member been diagnosed with lung cancer?
      Are you already active in providing lung cancer support and/or education to others?
      Do you want to ramp up your advocacy work and learn more about the science of lung cancer research?

    THEN …

    Apply for the brand-new STARS (Supportive Training for Advocate in Research and Science) program!  STARS was developed by the IASLC (International Association for the Study of Lung Cancer) in collaboration with international lung cancer patient research advocates and advocacy nonprofits.

    Those accepted in the program will be assigned a mentor from their own country, meet and learn lung cancer science from researchers, develop science communication skills, and attend the World Conference on Lung Cancer (WCLC) in Barcelona, Spain in September 2019.

    To learn more and to find the online application, click here:
    https://www.iaslc.org/supportive-training-advocates-research-and-science-stars

    The application period is open from March 8 to May 1, 2019. Hope you’ll apply!

    Median survival for metastatic ALK+ lung cancer can be more than SIX YEARS!

    Finally! A published study offers proof that metastatic ALK+ lung cancer patients can live for YEARS thanks to targeted therapies.

    This is phenomenal, considering that in 2011 (the year crizotinib was approved in the US for ALK+ non-small cell lung cancer, or ALK+ NSCLC) , the US SEER database listed average survival for metastatic non-small cell lung cancer at less than one year.

    In this study of 110 patients at University of Colorado (one of the sites in the original clinical trial of crizotinib for ALK+ NSCLC), the median overall survival time from diagnosis of stage IV disease was 81 months. That’s 6.8 years.

    Over six YEARS of survival.  Woohoo!  Note that this median survival (when 50% of the group remains alive) will be even longer for patients diagnosed after 2011, when crizotinib was approved.

    Besides finding patients with stage IV ALK-positive NSCLC can have prolonged overall survival, the study also found:

    • Brain metastases at diagnosis of stage IV disease does not influence overall survival. (Wow. Brain mets aren’t an automatic death sentence.)
    • Having more organs involved with tumor at stage IV presentation is associated with worse outcomes. (Bummer, but we can work on that.)
    • Prolonged benefit from pemetrexed chemo is associated with better outcomes (some patients in the study had chemo before or after a targeted therapy). 

    Yay for cancer research that is helping more lung cancer patients live longer!  You can read the complete article here.

    Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer
    Jose M. Pacheco, MD et al, University of Colorado Cancer Center

    Ah, the life of a research advocate …

    Life as a lung cancer research advocate can require a lot of travel. This week I’m in Washington DC for two meetings.

    Monday I participated as the sole patient advocate in the National Cancer Institute’s Small Cell Lung Cancer (SCLC) working group meeting, along with some of the top US researchers in this disease. The meeting will provide fodder for the NCI’s report to Congress about the Recalcitrant Cancers Act.

    Thursday I’ll be one of several patient advocates at the National Institutes of Medicine for a meeting on data sharing, along with medical institutions, pharma, and healthcare payers. Data sharing in the electronic age involves more than just who can see your medical records. We patients and family members have already participated in several phone calls in preparation for this meeting. It will be interesting to hear what the other stakeholder groups think are the main barriers to data sharing, and what we should do about them.

    In between, I’m trying to get caught up on expense reports and writing projects while adjusting to a new time zone. I hope my inputs make a enough difference for patients to make the travel worthwhile.